Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Eupraxia Pharmaceuticals Inc (EPRX.TO)

Eupraxia Pharmaceuticals Inc (EPRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth GlobeNewswire - Mon Jul 13, 3:05PM CDT

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“ Eupraxia ” or the “ Company ”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization GlobeNewswire - Tue Jul 7, 7:00AM CDT

VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders GlobeNewswire - Fri Jun 19, 3:02PM CDT

VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“ Eupraxia ” or the “ Company ”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 7:00AM CDT

VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results GlobeNewswire - Tue May 12, 4:00PM CDT

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Stocks in play: Eupraxia Pharmaceuticals Inc. Baystreet - Wed May 6, 8:11AM CDT

Announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System ...

EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week GlobeNewswire - Wed May 6, 6:00AM CDT

EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) GlobeNewswire - Tue May 5, 6:00AM CDT

EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer GlobeNewswire - Fri May 1, 4:05PM CDT

VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 6.51 (+1.72%)
EPRX.TO : 8.98 (-1.32%)
Stocks in play: Eupraxia Pharmaceuticals Inc. Baystreet - Wed Apr 22, 8:49AM CDT

Announced that the Company will present 4 abstracts at Digestive Disease Week Annual meeting being held ...

EPRX.TO : 8.98 (-1.32%)

Barchart Exclusives

Amazon Just Surpassed $3 Trillion Market Cap. What Comes Next for AMZN Stock. Barchart - 22 minutes ago
Amazon has achieved the $3 trillion market cap milestone, but options pricing suggests AMZN shares will rip higher from here in the second half of 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.